Award recognizes scientific breakthroughs
Phoenix, AZ, November 17, 2005- The Translational Genomics
Research Institute (TGen) today announced that Dr. Mitsutoshi
Nakada, an associate investigator in the Brain Tumor Research Unit,
has received the prestigious Hoshino Award from the Japan Society
for Neuro-Oncology for his work in discovering new therapeutic
targets for primary brain tumors.
"Dr. Nakada is an exceptionally dedicated and disciplined
researcher who shows compassion for brain tumor patients and
demonstrates urgency in his approach to developing new therapies
through translational research," said Dr. Michael Berens, Senior
Investigator at TGen. "He is an integral member of the Brain Tumor
Unit at TGen."
A two-year fellowship award from the Japan Society for the
Promotion of Science supports Dr. Nakada's work at TGen. His
research focuses on searching for new therapeutic targets on
primary brain tumors called gliomas. Dr. Nakada has made
fundamental discoveries on the role of a family of genes called
ephrins, which control processes in the brain during normal
development, such as how neurons connect with one another, how
blood vessels form, and how cells migrate in the brain. His
research at TGen led to the discovery that ephrins help mediate
glioma cell invasion.
In addition to receiving the Hoshino Award, which recognizes
outstanding achievements in the field of brain tumor research, Dr.
Nakada presented a lecture at the 23rd Annual Meeting of the Japan
Society for Neuro-Oncology. Since 1993, the Japan Society for
Neuro-Oncology has annually selected one Japanese Neuro-Oncologist
to receive the Hoshino Award. The award was named after
internationally recognized brain tumor researcher, Dr. Takao
Hoshino, who is a former professor in the Department of
Neurosurgery at the University of California, San Francisco. Dr.
Hoshino died from gastric cancer at the age of 55 in 1993.
Prior to joining TGen, Dr. Nakada spent seven years as a
neurosurgeon at Kanazawa University Hospital in Japan. He has
conducted basic brain tumor research since 1997 in addition to his
work as a neurosurgeon. His research in Japan showed a strong
interaction between extra cellular matrix degradation enzymes and
glioma cells during the invasive process and then he identified a
specific inhibitor of the enzyme.
# # #
About TGen
The mission of the Translational Genomics Research Institute
(TGen) is to make and translate genomic discoveries into advances
in human health. Translational genomics research is a relatively
new field employing innovative advances arising from the Human
Genome Project and applying them to the development of diagnostics,
prognostics and therapies for cancer, neurological disorders,
diabetes and other complex diseases. TGen is focused on
personalized medicine and plans to accomplish its goals through
robust and disease-focused research.
Media Contact:
Amy Erickson-TGen (602) 343-8522